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ABSTRACT
Background: Phenytoin can induce diversified adverse reactions including generalized eruptions and the hy-
persensitivity syndrome. Delayed-type allergic mechanisms have been postulated to underlie these reactions.
The tests most widely used to detect T-cell sensitization to drugs are the patch test and the lymphocyte trans-
formation test (LTT), but their sensitivity is not sufficient. Simultaneous assessment of both the frequencies and
the cytokine-producing phenotypes of allergen-specific T cells has become possible with the recently intro-
duced carboxyfluorescein succinimidyl ester (CFSE) assay.
Methods: Seven patients who presented with phenytoin-induced maculopapular exanthema with and without
fever were included in this study. Peripheral blood mononuclear cells (PBMCs) were labeled with CFSE and
cultured with phenytoin for seven days. The cells were stained with anti-CD4 and cytokine-specific monoclonal
antibodies (MoAbs), and analyzed with FACSCalibur.
Results: The phenytoin-specific proliferation of CD4+ cells in patients was significantly higher than in the four
controls exposed to phenytoin, and in seven healthy children with no previous phenytoin intake. A significant
difference in the percentages of CD4+ IFN-γ+ cells between patients and the seven healthy children was ob-
served. The sensitivity and specificity of proliferation were 100% and 90.9%, and those of IFN-γ secretion were
71.4% and 100%, respectively.
Conclusions: Phenytoin-specific proliferation may be detected with greater sensitivity by the CFSE dilution
assay than the conventional LTT. The assay revealed that both CD4+ and CD4− T cells proliferated and pro-
duced IFN-γ and TNF-α after stimulation with phenytoin. The CFSE dilution assay might be useful for the diag-
nosis and understanding of drug hypersensitivity.
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Table 1 Characteristics of Patients
Hypersensitivity to PHT
Neurological AbnormalitiesSexAge (years)Case Interval between
Reaction and Analysis (month)Symptoms
19fever, exanthemalissencephaly, mental retarda
tion, symptomatic epilepsy
M 21
 1exanthemasymptomatic epilepsyF 32
40exanthemalissencephaly, mental retarda
tion, symptomatic epilepsy
M 43
 6exanthemafrontal lobe epilepsyF 54
51exanthemamental retardation, sympto
matic epilepsy
F115
50exanthemafrontal lobe epilepsyM116
12fever, exanthemafrontal lobe epilepsyM137
INTRODUCTION
Phenytoin is an effective and widely prescribed anti-
convulsant agent used in the treatment of focal and
generalized tonic clonic seizures.1 Phenytoin can in-
duce eruptions that include maculopapular exan-
thema, the Stevens-Johnson syndrome, generalized
exfoliative dermatitis, toxic epidermal necrolysis, vas-
culitis and fixed drug eruptions. Phenytoin is also
linked to a hypersensitivity syndrome that manifests
with fever, rash and lymphadenopathy.2 Allergic
mechanisms have been postulated to underlie these
diversified adverse reactions.3
The clinical signs and symptoms of allergic reac-
tions to drugs are extremely heterogeneous4 and in-
clude different allergic reactions such as immediate-
type reactions including anaphylaxis, type II and III
reactions such as purpura and hypersensitivity vascu-
litis, as well as delayed-type reactions.5,6 For all types
of allergic reactions, recognition of the antigen by
specifically sensitized T-lymphocytes is a prerequi-
site. In the case of delayed-type hypersensitivity reac-
tions to aromatic anticonvulsant drugs such as pheny-
toin, the detection of allergen-specific T cells is espe-
cially important for diagnosis because of the absence
of allergen-specific IgE.7
Currently, both in vivo and in vitro tests are used
for the detection of sensitized T cells. Although an in
vivo patch test with the suspected compound has
been reported to be helpful in determining the cause
of drug allergy, the reported sensitivity is relatively
low (31.7―50%).8,9 The test most widely used to detect
T-cell sensitization to drugs in vitro is a lymphocyte
transformation test (LTT),10,11 which measures 3H-
thymidine uptake of dividing cells. Although it has
been in use for more than three decades, many labo-
ratories do not achieve sufficient sensitivity with this
test.10 An alternative for the measurement of T-cell
proliferation as a read out of LTT is the determination
of antigen-dependent-expressed proteins such as cy-
tokines. IFN-γ and IL-5 have been reported to be use-
ful indicators of drug-specific T-cell activation.11,12
Recently, Turcanu et al. introduced a carboxyfluo-
rescein succinimidyl ester (CFSE) assay to identify
food antigen-specific T cells.13 CFSE is a membrane-
permeating dye that binds the amino groups of cyto-
plasmic proteins with its succinimidyl-reactive group.
When cells divide, CFSE-labeled proteins are equally
distributed between the daughter cells, thus halving
cell fluorescence with each division. Consequently,
antigen-specific T cells lose their fluorescence after
culture in the presence of the respective antigen
(CFSElow) and are distinguishable from other cells in
culture (CFSEhigh). In this report, we applied this ex-
perimental approach to examine both the frequencies
and cytokine-producing phenotypes of these
phenytoin-specific CD4+ and CD4− T cells simultane-
ously.
METHODS
PATIENTS AND CONTROLS
Seven patients presenting with phenytoin-induced
maculopapular exanthema with and without fever
were included in this study (Table 1). Informed con-
sent was obtained from all patients participating in
this study. The study was approved by the local medi-
cal ethics committee.
Two control groups were included in the investiga-
tion. In the first control group (control A), four indi-
viduals exposed to phenytoin without clinical signs of
a drug-allergic reaction were investigated. In the sec-
ond control group (control B), seven healthy children
with no previous phenytoin intake were examined.
CFSE DILUTION ASSAY
The frequencies and cytokine-producing phenotypes
of phenytoin-specific T cells were examined simulta-
neously using a CFSE dilution assay according to
Turcanu et al. with some modifications.13 Briefly, pe-
ripheral blood mononuclear cells (PBMCs) isolated
from heparinized venous blood by centrifugation on
Ficoll-Paque (Pharmacia, Uppsala, Sweden) were in-
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Fig. 1 Representative results from patient 3. PBMCs from patient 3 were isolated, labeled with CFSE, and cultured in the pres-
ence of 50 μg/ml of phenytoin. On day 7, PBMCs were restimulated with PMA and ionomycin in the presence of brefeldin A for 6 
hours, then the cytokine production of PC-5-labeled CD4+ cels was assessed using intracelular cytokine staining with the PE-
labeled MoAbs indicated. A represents the background levels of CFSElow cels in CD4 ＋ (left upper quadrant) and CD4 －cels (left 
lower quadrant) in culture without phenytoin. B represents the percentages of CFSElow cels in CD4 ＋ (left upper quadrant) and 
CD4 － (left lower quadrant) cels in culture with phenytoin. C to E show the percentage of indicated cytokine-positive cels in 
phenytoin-specific CFSElow  CD4 ＋ cels,  F  to H show the percentages of cytokine-positive cels in phenytoin-specific CFSElow 
CD4 － cels.
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cubated with CFSE (Sigma, St. Louis, MO, USA, la-
beling concentration of 5 µM) for 10 minutes at 37℃,
and excess dye was washed away. CFSE-labeled
PBMCs were then cultured with 50 µgml of pheny-
toin (Aleviatin, Dainippon-Sumitomo, Japan) in RPMI-
1640 supplemented with 5% autologous plasma at a
concentration of 1×106 cellsml under humidified
conditions and 5% CO2. After seven days of culture,
PBMCs were restimulated with PMA (50 ngml)
(Sigma) and ionomycin (1 µgml) (Sigma) in the
presence of brefeldin A (10 µgml) (Sigma) for six
hours. The cells were then stained with PC-5-labeled
anti-CD4 antibody, fixed and permeabilized with FIX
& PERM cell permeabilization kits (Caltag Laborato-
ries, Burlingame, CA, USA) and stained with PE-
labeled IFN-γ, IL-4, TNF-α or IL-10 specific monoclo-
nal antibodies (MoAbs; Immunotech Coulter; Miami,
FL, USA). Stained cells were acquired with FACSCali-
bur (BD Biosciences, Milpitas, CA, USA) and the
data were analyzed with CellQuest software (BD Bi-
osciences).
STATISTICAL ANALYSIS
Statistical significance was measured by the two-
tailed Kruskal-Wallis one-way ANOVA for ranks fol-
lowed by the Mann-Whiney U test with Bonferroni
corrections for individual groups using SPSS software
(SPSS Inc., Chicago, IL, USA).
RESULTS
A SIGNIFICANTLY HIGH NUMBER OF CFSElow
CD4+ AND CD4− T LYMPHOCYTES APPEARED
IN PATIENTS AFTER PHENYTOIN STIMULATION
PBMCs from patients were labeled with CFSE and
then cultured for seven days in the presence of
phenytoin. In Figure 1, representative results from
patient 3 are shown. In phenytoin-treated cultures,
considerable populations of CFSElow CD4+ and CD4−
T lymphocytes emerged (17.1% and 6.12% of CD4+
and CD4− cells, respectively)(Fig. 1B); however, the
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Fig. 2 Proliferation of phenytoin-specific T lymphocytes. 
PBMCs were isolated, CFSE-labeled, and cultured in the 
presence of phenytoin for 7 days, then the percentage of 
antigen-specific CFSElow CD4 ＋ cels in CD4 ＋ cels (A) and 
CFSElow CD4 － cels in CD4 － cels (B) was assessed by flow 
cytometry. Points represent data from diferent individuals, 
while bars show the median values. Statistical significance 
was measured by the Kruskal-Walis one-way ANOVA for 
ranks folowed by the Mann-Whiney U test with Bonferoni 
corections for individual groups ( ＊＊p＜0.01, ＊p＜0.05).
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proportions of CFSElow cells were small when
PBMCs were cultured without phenytoin (0.61% and
0.65% of CD4+ and CD4− cells, respectively)(Fig. 1A).
Phenytoin-specific proliferation was calculated by
subtracting the proportion of CFSElow cells without
stimulation from the proportion after phenytoin
stimulation, and these results are presented in Figure
2. Phenytoin-specific proliferation of CD4+ cells in pa-
tients was significantly higher than in Control A ex-
posed to phenytoin (median 4.41%, range 0.26 to
17.1% vs. median 0.07%, range 0.0 to 1.83%, p < 0.05)
(Fig. 2A), and in seven healthy children with no pre-
vious phenytoin intake (Control B) (median 4.41%,
range 0.26 to 17.1% vs. median 0.0%, range 0.0 to
0.12%, p < 0.01) (Fig. 2A).
Similar tendencies were seen in the phenytoin-
specific proliferation of CD4− cells, although statisti-
cal significance was weaker. Phenytoin-specific prolif-
eration of CD4− cells in patients was significantly
higher than in Control B (median 2.36%, range 0.04 to
5.46% vs. median 0.04%, range 0.0 to 0.25%, p < 0.05)
(Fig. 2B), but was not significantly different from that
in Control A (median 2.36%, range 0.04 to 5.46% vs.
median 0.04%, range 0.0 to 0.52%).
PHENYTOIN-SPECIFIC T CELLS DISPLAY TH1
DOMINANCE
Figures 1C to 1H demonstrate representative results
of cytokine production. We expressed the results as a
percentage of cytokine-positive cells among CFSElow
(antigen-specific) lymphocytes: 78.1%, 7.52% and
71.6% of CFSElow CD4+ cells and 68.4%, 1.86% and
44.9% of CFSElow CD4− cells were stained with PE-
labeled antibody to IFN-γ, IL-4 and TNF-α, respec-
tively.
We compared the cytokine production of
phenytoin-specific CD4+ cells for all study groups. A
significant difference in the percentages of IFN-γ+
cells between patients and Control B (median 59.5%,
range 0 to 78.1% vs. median 0%, range 0 to 5.65; p <
0.05) was observed (Fig. 3A), but the percentage in
patients was not significantly different from that in
Control A (median 59.5%, range 0 to 78.1% vs. median
0%, range 0 to 24.3%). A similar tendency was ob-
served in percentages of IFN-γ+ cells among CD4−
cells, but the differences were not statistically signifi-
cant.
Phenytoin-specific T cells did not seem to secrete
considerable levels of IL-4, and there was no signifi-
cant difference in the percentages of IL-4+ CFSElow
cells from patients and controls (Figs. 3C, 3D). TNF-
α-positive cells tended to correlate with INF-γ-positive
cells (data not shown).
DETECTION OF PHENYTOIN-SPECIFIC PROLIF-
ERATION AND IFN-γ SECRETION OF CD4+
CELLS PROVED SENSITIVE PARAMETERS
The detection of drug-specific proliferation and IFN-γ
secretion from the CD4+ cells of the seven patients
proved reliable sensitive parameters for the detection
of drug sensitization (Table 2). The sensitivity, speci-
ficity, positive and negative predictive values (PPV
and NPV) were calculated and the best cut-off points
(0.26% for proliferation and 24.3% for IFN-γ produc-
tion) were selected as those that maximized the sum
of the specificity and sensitivity. Differences in the
calculated sensitivity of proliferation (100%) and IFN-γ
secretion (71.4%) resulted only from a control subject
who showed a high percentage of IFN-γ-secreted
cells. The specificity of the proliferation was relatively
low (90.9%) because the low proliferative response of
PBMC from a patient decreased the cut off point.
This patient had a history of maculopapular exan-
thema following phenytoin intake six months before
this examination.
DISCUSSION
In the LTT, allergen-stimulated lymphocytes undergo
Allergen-specific T-cell Response in Patients with Phenytoin Hypersensitivity
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Fig. 3 Intra-cytoplasmic cytokine profiles of antigen-specific T lymphocytes. PBMCs were isolated, CFSE-labeled, and 
cultured in the presence of phenytoin for 7 days, then the cytokine-producing phenotype of antigen-specific (CFSElow) 
CD4 ＋ (A, C) and CD4 － (B, D) cels was assessed by flow cytometry. Intra-cytoplasmic cytokine profiles were presented 
as percentages of CFSElow cels that produce IFN-γ (A, B) and IL-4 (C, D). Points represent data from diferent individu-
als, while bars show the median values. Statistical significance was measured by the Kruskal-Walis one-way ANOVA for 
ranks folowed by the Mann-Whiney U test with Bonferoni corections for individual groups ( ＊p ＜ 0.05).
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blastogenesis and generate lymphokines such as IL-
2, followed by a proliferative response that can be
measured by the incorporation of 3H-thymidine dur-
ing DNA synthesis. Retrospective evaluation of the
sensitivity and specificity of the LTT to β-lactam anti-
biotics revealed a sensitivity of 78% and a specificity of
85%, better than the patch test (64% and 85%, respec-
tively).14 However, the sensitivity achieved by many
laboratories does not achieve such a level, despite the
fact that the LTT has been in use for more than three
decades.10 An alternative for the measurement of T-
cell proliferation as a read out of the LTT is the deter-
mination of antigen-induced proteins such as cytoki-
nes. IFN-γ has been reported to present a useful indi-
cator of drug-specific T-cell activation.15 Sachs et al.
reported that the specific activation of peripheral
blood mononuclear cells consistently resulted in IL-5
secretion, and that the sensitivities of the patch test,
the LTT, and the assessment of drug-specific IL-5 se-
cretion for the detection of drug sensitization were
55, 75, and 92%, respectively.12
In this study we demonstrated that phenytoin-
specific proliferation and cytokine production of
PBMC from seven patients with phenytoin hypersen-
sitivity could be detected by the CFSE dilution assay.
The determination of phenytoin-specific CD4+ cell
proliferation and INF-γ production by this assay re-
sulted in more sensitive parameters (100% and 71.4%,
respectively) for the detection of drug-sensitized T
cells than the LTT or patch tests. Although both the
CFSE and LTT assays detect lymphocyte prolifera-
tion, it is possible to examine proliferations of CD4+
and CD4− cells separately but simultaneously by the
CFSE assay. Furthermore, true antigen specific cells
which divided several times in the culture might be
distinguished from bystander cells that divided a few
times at the late phase of culture. Thus, our results
revealed the potential of the CFSE dilution analysis,
although, a study involving a larger number of sub-
jects is necessary to establish the superiority of the
CFSE assay to the LTT. As use of this method could
be applied to other drugs, the CFSE dilution analysis
might provide a non-radioactive, sensitive alternative
for the in vitro detection of drug sensitization.
It has been shown that in primary cultures of
PBMCs both CD4+ and CD8+ T lymphocytes are acti-
Tsuge I et al.
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Table 2 Diagnostic Accuracy of CD4 ＋ cel Proliferation and IFN-γ Secretion
NPV ＊ (%)PPV ＊ (%)Specificity (%)Sensitivity (%)
Results
Negative †Positive †
10087.590.9100Proliferation
 07Patient
101Control
84.610010071.4IFN-γ secretion
 25Patient
110Control
†Cut-of points were 0.26% for proliferation and 24.3% for IFN-γ production.
＊PPV denotes positive predictive value, NPV denotes negative predictive value.
vated by drugs.16 As T-cell activation with a particular
function seems to lead to a specific clinical picture of
hypersensitivity, the intensive characterization of
drug-specific T cells might contribute to the diagno-
sis and understanding of drug hypersensitivity. In
this respect, the cloning of antigen-specific T cells
has proven to be a powerful tool to investigate the im-
mune response to allergens at the T-cell level.17,18
Nevertheless, several cycles of T cell stimulation in
the presence of antigen, feeder cells, and exogenous
cytokines are necessary to establish T cell clones.
Since this is both time and labor consuming, only a
limited number of clones can be studied. Further-
more, human T cells tend to develop a TH2-skewed
cytokine-producing phenotype after repeated stimula-
tion in vitro under neutral conditions.19
In this report, using the CFSE dilution assay we re-
vealed that both CD4+ and CD4− phenytoin-specific T
cells existed and that both mainly produced IFN-γ
and TNF-α (Th1 and Tc1). A small population of
CD4+ cells secreted IL-4 (Th2). Pichler proposed that
further classification of delayed-type (type IV) hyper-
sensitivity reactions through the release of certain cy-
tokines and chemokines led to a better understand-
ing of drug hypersensitivity pathogenesis:7 Type IVa,
Th1 cells activate and recruit monocytes; Type IVb,
Th2 cells activate and recruit eosinophils; Type IVc,
Tc cells develop cytotoxicity; and Type IVd, IL-8 se-
creting T cells activate and recruit neutrophils. The
CFSE dilution assay combined with cytoplasmic IL-8
or perforin staining besides INF-γ and IL-4 might pro-
vide further insight into various drug allergies.
In summary, we analyzed phenytoin-specific T-cell
proliferation and cytokine production simultaneously
using the CFSE dilution assay. Phenytoin-specific
proliferation may be detected with greater sensitivity
by the CFSE dilution assay than the conventional
LTT. Furthermore, the assay revealed that both CD4+
and CD4− T cells proliferated and produced IFN-γ and
TNF-α after stimulation with phenytoin, suggesting
that both Th1 and Tc1 participated in the pathogene-
sis. The CFSE dilution assay might be useful for the
diagnosis and understanding of drug hypersensitiv-
ity.
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